DPP4 and cardiovascular disorder: In the assessment of risks of cardiovascular diseases associated with antidiabetic drugs in patients with type 2 diabetes, Ou et al. found that DPP-4 inhibitor users had a significantly lower risk for MACE, stroke, myocardial infarction, and HF than that of meglitinides and insulin, but higher than that of metformin users (Ou et al., 2016).